Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Jaktinib in Healthy Volunteers
NCT03314402Phase 1Completed
- Sponsor
- Zelgen
- Start
- Sep 2017
- Primary completion
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in myelofibrosis (MF) comparing Jaktinib with Placebo (2 arms). Primary endpoint: Maximum Tolerated Dose up to 6 months. Started Sep 2017; status: completed.
02
Drugs
jaktinib
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NCT03314402.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03314402.